[FOR RELEASE August 5, 2019 China Biologic Reports Financial Results for the Second Quarter of 2019 —2Q19 Total Sales Up 12.7% YoY in USD terms, or 20.4% YoY in RMB terms; Net Income Up 45.5% YoY to $41.6 Million; Non-GAAP Adjusted Net Income Up 29.1% YoY in RMB terms — —1H19 Total Sales Up 14.0% YoY]
[FOR RELEASE August 5, 2019 China Biologic Reports Financial Results for the Second Quarter of 2019 —2Q19 Total Sales Up 12.7% YoY in USD terms, or 20.4% YoY in RMB terms; Net Income Up 45.5% YoY to $41.6 Million; Non-GAAP Adjusted Net Income Up 29.1% YoY in RMB terms — —1H19 Total Sales Up 14.0% YoY]
[O2Micro Reports Second Quarter 2019 Financial Results GEORGE TOWN, Grand Cayman, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Operational and Strategic Highlights: Q2 2019 sequential quarterly revenue was up 11.8% exceeding guidance provided on March 29, 2019 GAAP net loss per fully diluted ADS in the second q]
[O2Micro Reports Second Quarter 2019 Financial Results GEORGE TOWN, Grand Cayman, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Operational and Strategic Highlights: Q2 2019 sequential quarterly revenue was up 11.8% exceeding guidance provided on March 29, 2019 GAAP net loss per fully diluted ADS in the second q]
[Fanhua Provides Update on its Share Buyback Program for the Week of July 29, 2019 GUANGZHOU, China, August 5, 2019, (GLOBE NEWSWIRE) -- Fanhua Inc. (“Fanhua” or “the Company”) (Nasdaq: FANH), a leading independent financial services provider in China, today announced that it has repurchased 23,510 o]
[Fanhua Provides Update on its Share Buyback Program for the Week of July 29, 2019 GUANGZHOU, China, August 5, 2019, (GLOBE NEWSWIRE) -- Fanhua Inc. (“Fanhua” or “the Company”) (Nasdaq: FANH), a leading independent financial services provider in China, today announced that it has repurchased 23,510 o]
